OMEICOS Therapeutics
Robert’s passion is to transform excellent science into novel treatments for diseases with high unmet medical need. Prior to taking the lead at OMEICOS, he worked as a clinical cardiologist at the Charité – Universitätsmedizin Berlin and led and participated in many clinical and preclinical research in activities together with the Max-Delbrück-Center for Molecular Medicine. Robert holds a PhD in cardiovascular physiology from the Freie Universität zu Berlin and received Board-certification for Internal Medicine.
OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.